The efficacy and tolerability of irbesartan in patients with mild-moderate essential hypertension

Objectives To observe the efficacy and tolerability of irbesartan in patients with mild moderate essential hypertension. Methods 186 patients with mild moderate essential hypertension were recruited. All patients were treated with irbesartan for 12 weeks. Results After 2,4,6,8,12 weeks of treatment, prominent efficacy rate were 40 3%, 47 3%, 54 4%, 63 2%, 71 1% respectively, efficacy rate were 12 3%, 17 3%, 20 9%, 22 6%, 23 3% respectively, total efficacy rate were 52 6%, 64 6%, 75 3%, 85 8%, 94 4% respectively. A significant reduction in systolic and diastolic and mean blood pressure was found after only two weeks of therapy with irbesartan. The longer irbesartan was used, the lower reduction of blood pressure was found. The lowest reduction of blood pressure was found after 12 weeks of therapy with irbesartan. There were no serious adverse event during 12 weeks of therapy. Conclusions The antihypertensive treatment with irbesartan is effective and safety in the most mild moderate essential hypertension. The antihypertensive efficacy of irbesartan is similar in patients with different ages and different body mass index.